NCT04872218View on ClinicalTrials.gov

Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

May 10, 2024

Study Completion Date

November 4, 2024

Conditions
Peanut Allergy
Interventions
DRUG

Abatacept

24 week treatment of IV abatacept following recommended dosages from the monograph

DRUG

Placebo

24 week treatment of IV placebo following recommended dosages from the abatacept monograph

OTHER

Peanut oral immunotherapy

Peanut oral immunotherapy, following a patient-driven protocol, starting 24 to 72h after the first administration of abatacept or placebo.

Trial Locations (1)

H3T1C5

CHU Sainte-Justine, Montreal

All Listed Sponsors
lead

Philippe Bégin

OTHER